S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:SAGE

Sage Therapeutics Stock Forecast, Price & News

$76.98
+6.33 (+8.96 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$68.23
Now: $76.98
$77.17
50-Day Range
$70.65
MA: $84.19
$96.76
52-Week Range
$25.01
Now: $76.98
$98.39
Volume641,303 shs
Average Volume512,617 shs
Market Capitalization$4.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics logo

Headlines

Sage Therapeutics EPS of $18.19
February 25, 2021 |  seekingalpha.com
Recap: Sage Therapeutics Q4 Earnings
February 24, 2021 |  benzinga.com
Sage Therapeutics Rises After Swing to Profit on Biogen Deal
February 24, 2021 |  finance.yahoo.com
Is SAGE A Good Stock To Buy According To Hedge Funds?
December 22, 2020 |  finance.yahoo.com
Should You Buy Sage Stock After the Biogen Investment?
December 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380
Employees675
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.87 million
Book Value$18.23 per share

Profitability

Net Income$-680,240,000.00
Net Margins-7,706.84%

Miscellaneous

Market Cap$4.49 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

894th out of 1,972 stocks

Pharmaceutical Preparations Industry

429th out of 772 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$76.98
+6.33 (+8.96 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

Is Sage Therapeutics a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sage Therapeutics?

Wall Street analysts have given Sage Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Sage Therapeutics
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings results on Wednesday, February, 24th. The biopharmaceutical company reported $18.19 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.17) by $20.36. Sage Therapeutics had a negative trailing twelve-month return on equity of 63.81% and a negative net margin of 7,706.84%.
View Sage Therapeutics' earnings history
.

How has Sage Therapeutics' stock price been impacted by Coronavirus?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have increased by 82.0% and is now trading at $76.98.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SAGE?

17 analysts have issued 12-month target prices for Sage Therapeutics' shares. Their forecasts range from $28.00 to $135.00. On average, they expect Sage Therapeutics' share price to reach $80.50 in the next year. This suggests a possible upside of 4.6% from the stock's current price.
View analysts' price targets for Sage Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 59, Pay $536.37k)
  • Mr. Michael Cloonan, Chief Operating Officer (Age 50, Pay $582.75k)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 59, Pay $564.84k)
  • Dr. Jeffrey M. Jonas, Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 68, Pay $983.77k)
  • Dr. Stephen J. Kanes, Chief Medical Officer (Age 56, Pay $580.67k)
  • Mr. Barry E. Greene, Pres, CEO & Director (Age 58)
  • Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 60)
  • Mr. Matthew Calistri, VP of Investor Relations
  • Ms. Erin E. Lanciani, Sr. VP of People & Organizational Strategy (Age 52)

Who are some of Sage Therapeutics' key competitors?

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.59%), Price T Rowe Associates Inc. MD (4.53%), Janus Henderson Group PLC (3.80%), Artisan Partners Limited Partnership (3.06%), Victory Capital Management Inc. (1.41%) and Jennison Associates LLC (1.08%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Michael Cloonan and Steven M Paul.
View institutional ownership trends for Sage Therapeutics
.

Which major investors are selling Sage Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Price T Rowe Associates Inc. MD, Morgan Stanley, BlackRock Inc., Nuveen Asset Management LLC, Federated Hermes Inc., The Manufacturers Life Insurance Company , and UBS Asset Management Americas Inc..
View insider buying and selling activity for Sage Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sage Therapeutics stock?

SAGE stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Davidson Kempner Capital Management LP, Great Lakes Advisors LLC, Artal Group S.A., First Trust Advisors LP, Artisan Partners Limited Partnership, and Jennison Associates LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $76.98.

How much money does Sage Therapeutics make?

Sage Therapeutics has a market capitalization of $4.49 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 675 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is www.sagerx.com.

Where are Sage Therapeutics' headquarters?

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.